Study of <scp>SOX</scp> combined with intraperitoneal high‐dose paclitaxel in gastric cancer with synchronous peritoneal metastasis: A phase <scp>II</scp> single‐arm clinical trial

Tu, Li; Zhang, Weihan; Ni, Lu; Xu, Zihan; Yang, Kun; Gou, Hongfeng; Zhu, Qing; Liu, Ming; Yu, Yang; Hu, Jian‐Kun; Qiu, Meng

doi:10.1002/cam4.5277

Cited by 11 publications

(12 citation statements)

References 30 publications

(73 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The JGCA classification evaluates the presence of positive cytology (C0 or C1) and the presence of macroscopic peritoneal metastases (P0 or P1) 36 , whereas the PCI scores the extent of macroscopic peritoneal disease in 13 pelvic–abdominal regions 37 . Three studies used the JGCA classification 21 , 27 , 29 , 14 studies reported the PCI score 13–18 , 22 , 25 , 30–35 and 5 studies used both methods 19 , 23 , 24 , 26 , 28 . One study did not report a classification for peritoneal metastases 20 .…”

Section: Resultsmentioning

confidence: 99%

“…Seventeen studies defined peritoneal disease as macroscopic peritoneal disease (that is, P1 on JGCA classification or PCI ≥ 1) 13 , 15–19 , 22 , 24–26 , 28 , 29 , 31–35 . The remaining six studies defined peritoneal disease as positive cytology in ascites or macroscopic peritoneal disease 14 , 20 , 21 , 23 , 27 , 30 . In 816 patients the peritoneal disease stage was described, of whom the majority (97%) had macroscopic peritoneal disease; 3% of patients had positive cytology only.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: a systematic review and meta-analysis

Guchelaar,

Nasserinejad,

Mostert

et al. 2024

British Journal of Surgery

View full text Add to dashboard Cite

Background Gastric cancer with peritoneal metastases is associated with a dismal prognosis. Normothermic catheter-based intraperitoneal chemotherapy and normothermic pressurized intraperitoneal aerosol chemotherapy (PIPAC) are methods to deliver chemotherapy intraperitoneally leading to higher intraperitoneal concentrations of cytotoxic drugs compared to intravenous administration. We reviewed the effectiveness and safety of different methods of palliative intraperitoneal chemotherapy. Methods Embase, MEDLINE, Web of Science and Cochrane were searched for articles studying the use of repeated administration of palliative intraperitoneal chemotherapy in patients with gastric cancer and peritoneal metastases, published up to January 2024. The primary outcome was overall survival. Results Twenty-three studies were included, representing a total of 999 patients. The pooled median overall survival was 14.5 months. The pooled hazard ratio of the two RCTs using intraperitoneal paclitaxel and docetaxel favoured the intraperitoneal chemotherapy arm. The median overall survival of intraperitoneal paclitaxel, intraperitoneal docetaxel and PIPAC with cisplatin and doxorubicin were respectively 18.4 months, 13.2 months and 9.0 months. All treatment methods had a relatively safe toxicity profile. Conversion surgery after completion of intraperitoneal therapy was performed in 16% of the patients. Conclusions Repeated intraperitoneal chemotherapy, regardless of method of administration, is safe for patients with gastric cancer and peritoneal metastases. Conversion surgery after completion of the intraperitoneal chemotherapy is possible in a subset of patients.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: a systematic review and meta-analysis

Guchelaar,

Nasserinejad,

Mostert

et al. 2024

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…High-dose intraperitoneal paclitaxel (80 mg/m 2 ) in 3-week cycles combined with oxaliplatin and S-1 showed comparable results with a 1-year overall survival rate of 82% and a median overall survival of 16.9 months [72]. In patients receiving intraperitoneal paclitaxel, several prognostic factors were discovered.…”

Section: Gastric Cancermentioning

confidence: 93%

“…Table 2 presents an overview of the reported portrelated complications in Phase II and Phase III studies [66][67][68][69][70][71][72][73][74][75][76][77][78][79][80][81]. Moreover, two retrospective studies focused on the complications of intraperitoneal access.…”

Section: Intraperitoneal Access Portmentioning

confidence: 99%

Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies

Guchelaar

Noordman

Koolen

et al. 2023

Drugs

View full text Add to dashboard Cite

Malignancies of the peritoneal cavity are associated with a dismal prognosis. Systemic chemotherapy is the gold standard for patients with unresectable peritoneal disease, but its intraperitoneal effect is hampered by the peritoneal-plasma barrier. Intraperitoneal chemotherapy, which is administered repeatedly into the peritoneal cavity through a peritoneal implanted port, could provide a novel treatment modality for this patient population. This review provides a systematic overview of intraperitoneal used drugs, the performed clinical studies so far, and the complications of the peritoneal implemental ports. Several anticancer drugs have been studied for intraperitoneal application, with the taxanes paclitaxel and docetaxel as the most commonly used drug. Repeated intraperitoneal chemotherapy, mostly in combination with systemic chemotherapy, has shown promising results in Phase I and Phase II studies for several tumor types, such as gastric cancer, ovarian cancer, colorectal cancer, and pancreatic cancer. Two Phase III studies for intraperitoneal chemotherapy in gastric cancer have been performed so far, but the results regarding the superiority over standard systemic chemotherapy alone, are contradictory. Pressurized intraperitoneal administration, known as PIPAC, is an alternative way of administering intraperitoneal chemotherapy, and the first prospective studies have shown a tolerable safety profile. Although intraperitoneal chemotherapy might be a standard treatment option for patients with unresectable peritoneal disease, more Phase II and Phase III studies focusing on tolerability profiles, survival rates, and quality of life are warranted in order to establish optimal treatment schedules and to establish a potential role for intraperitoneal chemotherapy in the approach to unresectable peritoneal disease. Supplementary Information The online version contains supplementary material available at 10.1007/s40265-022-01828-7.

show abstract

“…This drug also inhibits the effects of other factors on the microtubule system and, together with the stable binding of microtubule proteins, eventually induces apoptosis ( Liu et al, 2017a ). In clinical applications, paclitaxel has shown good efficacy in treating non-small cell lung cancer ( Hoang et al, 2012 ), breast cancer ( Manhas et al, 2022 ), gastric cancer ( Tu et al, 2022 ), nasopharyngeal cancer ( Xia et al, 2022 ), ovarian cancer ( Kong et al, 2023 )and cervical cancer ( Yasunaga et al, 2022 ), particularly for drug-resistant tumors ( Song et al, 2018 ; Kawiak et al, 2019 ). Although the therapeutic efficacy of paclitaxel in glioma has been confirmed, its therapeutic mechanism remains unclear.…”

Section: Introductionmentioning

confidence: 99%

Mechanism of action of paclitaxel for treating glioblastoma based on single-cell RNA sequencing data and network pharmacology

Rao

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Paclitaxel is an herbal active ingredient used in clinical practice that shows anti-tumor effects. However, its biological activity, mechanism, and cancer cell-killing effects remain unknown. Information on the chemical gene interactions of paclitaxel was obtained from the Comparative Toxicogenomics Database, SwishTargetPrediction, Binding DB, and TargetNet databases. Gene expression data were obtained from the GSE4290 dataset. Differential gene analysis, Kyoto Encyclopedia of Genes and Genomes, and Gene Ontology analyses were performed. Gene set enrichment analysis was performed to evaluate disease pathway activation; weighted gene co-expression network analysis with diff analysis was used to identify disease-associated genes, analyze differential genes, and identify drug targets via protein-protein interactions. The Molecular Complex Detection (MCODE) analysis of critical subgroup networks was conducted to identify essential genes affected by paclitaxel, assess crucial cluster gene expression differences in glioma versus standard samples, and perform receiver operator characteristic mapping. To evaluate the pharmacological targets and signaling pathways of paclitaxel in glioblastoma, the single-cell GSE148196 dataset was acquired from the Gene Expression Omnibus database and preprocessed using Seurat software. Based on the single-cell RNA-sequencing dataset, 24 cell clusters were identified, along with marker genes for the two different cell types in each cluster. Correlation analysis revealed that the mechanism of paclitaxel treatment involves effects on neurons. Paclitaxel may affect glioblastoma by improving glucose metabolism and processes involved in modulating immune function in the body.

show abstract

Study of SOX combined with intraperitoneal high‐dose paclitaxel in gastric cancer with synchronous peritoneal metastasis: A phase II single‐arm clinical trial

Cited by 11 publications

References 30 publications

Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: a systematic review and meta-analysis

Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: a systematic review and meta-analysis

Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies

Mechanism of action of paclitaxel for treating glioblastoma based on single-cell RNA sequencing data and network pharmacology

Contact Info

Product

Resources

About